Online citations, reference lists, and bibliographies.
← Back to Search

Structure-activity Relationship Of Novel And Known Inhibitors Of Human Dimethylarginine Dimethylaminohydrolase-1: Alkenyl-amidines As New Leads.

J. Kotthaus, D. Schade, Nikola Muschick, E. Beitz, B. Clement
Published 2008 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Recent studies demonstrated that inhibition of dimethylarginine dimethylaminohydrolase (DDAH) activity could be a new strategy to indirectly affect nitric oxide (NO) formation by elevating N(omega)-methylated L-arginine (NMMA, ADMA) levels. This approach is an alternate strategy for the treatment of diseases associated with increased NO-concentrations. To date, three classes of potent inhibitors are known: (1) pentafluorophenyl sulfonates (IC(50)=16-58 microM, PaDDAH), which are also inhibitors for the arginine deiminase; (2) the most potent inhibitors are based on indolylthiobarbituric acid (IC(50)=2-17 microM, PaDDAH), which were identified by virtual modelling; and (3) L-arginine analogs, whose best representative is N(omega)-(2-methoxyethyl)-L-arginine (IC(50)=22 microM, rat DDAH). Based on these known structures, we aimed to develop inhibitors for the human DDAH-1 with improved potency and better relative selectivity for DDAH-1 over NOS. Particularly, the binding pocket of the guanidine-moiety was investigated by screening differently substituted guanidines, amidines and isothioureas in order to collect information on possible binding modes in the active site. All substances were tested in a plate-reader format and HPLC assay and several potent inhibitors were identified with K(i)-values varying from 2 to 36 microM, with N(5)-(1-iminobut-3-enyl)-L-ornithine (L-VNIO) being the most potent inhibitor of the human DDAH-1 so far described. Besides these potent inhibitors alternate substrates for hDDAH-1 were identified as well.
This paper references
Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney.
T. Ogawa (1989)
10.1016/J.STR.2006.03.006
Structure of the mammalian NOS regulator dimethylarginine dimethylaminohydrolase: A basis for the design of specific inhibitors.
D. Frey (2006)
10.1021/JM970550G
Potent and selective inhibition of neuronal nitric oxide synthase by N(ω)-propyl-L-arginine
H. Q. Zhang (1997)
10.1016/S0008-6363(99)00162-5
Biological significance of endogenous methylarginines that inhibit nitric oxide synthases.
J. Leiper (1999)
10.1006/ABIO.2000.4805
A colorimetric 96-well microtiter plate assay for the determination of enzymatically formed citrulline.
M. Knipp (2000)
10.1016/0006-291X(92)91279-Y
Cytochrome P450 catalyzes the oxidation of N omega-hydroxy-L-arginine by NADPH and O2 to nitric oxide and citrulline.
J. L. Boucher (1992)
10.1080/07853890500472151
Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond
R. Böger (2006)
10.1016/J.NUMECD.2005.11.012
Endothelial dysfunction and oxidative stress in arterial hypertension.
P. Ferroni (2006)
10.1021/JM00084A020
NG-allyl- and NG-cyclopropyl-L-arginine: two novel inhibitors of macrophage nitric oxide synthase.
N. M. Olken (1992)
10.1021/JA0430200
Searching for DDAH inhibitors: S-nitroso-L-homocysteine is a chemical lead.
M. Knipp (2005)
10.1016/J.BBRC.2006.08.123
Reduction of Nω-hydroxy-l-arginine to l-arginine by pig liver microsomes, mitochondria, and human liver microsomes
B. Clement (2006)
10.1038/nm1543
Disruption of methylarginine metabolism impairs vascular homeostasis
J. Leiper (2007)
10.1081/DMR-120005643
REDUCTION OF N-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES
B. Clement (2002)
Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas.
E. Garvey (1994)
10.1016/S0304-3940(01)02214-5
Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease
T. Abe (2001)
10.1074/jbc.272.8.4959
1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivo*
E. Garvey (1997)
10.1006/GENO.2000.6262
Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins.
C. Tran (2000)
10.1016/J.PHARMTHERA.2004.11.011
Nitric oxide and penile erectile function.
N. Toda (2005)
10.1016/J.BMCL.2007.04.095
Discovery of inhibitors of the pentein superfamily protein dimethylarginine dimethylaminohydrolase (DDAH), by virtual screening and hit analysis.
B. Hartzoulakis (2007)
10.1021/bi701659n
Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation.
Scott P. Forbes (2008)
10.1021/JM050187A
Selective substrate-based inhibitors of mammalian dimethylarginine dimethylaminohydrolase.
S. Rossiter (2005)
10.1074/JBC.273.15.8882
N5-(1-Imino-3-butenyl)-L-ornithine. A neuronal isoform selective mechanism-based inactivator of nitric oxide synthase.
B. R. Babu (1998)
10.1016/S0076-6879(94)33028-X
Nitric-oxide synthase assays.
J. Hevel (1994)
10.1021/BI047407R
Characterization of a transient covalent adduct formed during dimethylarginine dimethylaminohydrolase catalysis.
E. Stone (2005)
10.1021/BI051341Y
Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: dimethylargininase and peptidylarginine deiminase.
E. Stone (2005)
10.1006/BBRC.1994.2371
N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase.
J. L. Boucher (1994)
10.1136/BMJ.1.5011.149-A
ADVANCES IN PHARMACOLOGY
J. H. Burn (1957)
10.1006/ABBI.1995.1356
N-nitro-L-arginine and N-monomethyl-L-arginine exhibit a different pattern of inactivation toward the three nitric oxide synthases.
D. Reif (1995)
10.1016/J.BMC.2007.11.066
Nδ-Methylated l-arginine derivatives and their effects on the nitric oxide generating system
J. Kotthaus (2008)
10.1016/J.JINORGBIO.2004.10.016
Structure-function studies on nitric oxide synthases.
H. Li (2005)
10.1111/j.1476-5381.1996.tb16069.x
Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase
R. Macallister (1996)
10.1042/bj3570593
Nitric oxide synthases: structure, function and inhibition.
W. K. Alderton (2001)
10.1161/01.ATV.20.9.2032
Does ADMA cause endothelial dysfunction?
J. Cooke (2000)
10.1074/JBC.M306787200
Structural Characterization and Kinetics of Nitric-oxide Synthase Inhibition by Novel N5-(Iminoalkyl)- and N5-(Iminoalkenyl)-ornithines*
Lynn E. Bretscher (2003)



This paper is referenced by
10.1016/j.phrs.2009.07.001
Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk.
R. Böger (2009)
10.1111/bph.12016
On the selectivity of neuronal NOS inhibitors
B. Pigott (2013)
10.1016/j.pharmthera.2010.02.005
Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease.
D. Schade (2010)
10.3389/fonc.2019.01455
Inhibition of Dimethylarginine Dimethylaminohydrolase (DDAH) Enzymes as an Emerging Therapeutic Strategy to Target Angiogenesis and Vasculogenic Mimicry in Cancer
J. Hulin (2019)
10.1039/c0ob01117g
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
10.1007/978-3-319-26009-9_4
Amidine-Based Compounds Affecting l-Arginine Metabolism
C. Maccallini (2017)
10.1002/cmdc.201000392
Characterization of C‐Alkyl Amidines as Bioavailable Covalent Reversible Inhibitors of Human DDAH‐1
M. Lluis (2011)
10.1039/c5ob01843a
Arginine analogues incorporating carboxylate bioisosteric functions are micromolar inhibitors of human recombinant DDAH-1.
S. Tommasi (2015)
10.1124/jpet.113.206847
A Novel and Potent Inhibitor of Dimethylarginine Dimethylaminohydrolase: A Modulator of Cardiovascular Nitric Oxide
Yohannes T. Ghebremariam (2014)
10.1177/1087057111417712
A Continuous, Fluorescent, High-Throughput Assay for Human Dimethylarginine Dimethylaminohydrolase-1
Thomas W. Linsky (2011)
10.1042/BJ20100960
Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).
J. Kotthaus (2011)
10.1038/nrd3358
The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis
J. Leiper (2011)
Untersuchung der Umsetzung asymmetrisch methylierter Argininedurch rekombinant hergestellte und native Dimethylarginin-Dimethylaminohydrolase-2
Karin S Altmann (2014)
10.1016/j.jmb.2009.06.083
Structure-based and random mutagenesis approaches increase the organophosphate-degrading activity of a phosphotriesterase homologue from Deinococcus radiodurans.
R. Hawwa (2009)
10.1002/ardp.200900060
Arylazoamidoximes and Related Compounds as NO‐modulators
A. Schroeder (2010)
10.1002/cbic.201200499
Dimethylarginine‐Dimethylaminohydrolase‐2 (DDAH‐2) Does Not Metabolize Methylarginines
Karin S Altmann (2012)
10.1177/1087057112441521
Development of a Dimethylarginine Dimethylaminohydrolase (DDAH) Assay for High-Throughput Chemical Screening
Yohannes T. Ghebremariam (2012)
10.1021/ML2000824
Screening for dimethylarginine dimethylaminohydrolase inhibitors reveals ebselen as a bioavailable inactivator.
Thomas W. Linsky (2011)
10.1016/J.TET.2009.12.034
Efficient access to polysubstituted amidines, benzimidazoles and pyrimidines from amides
J. Wang (2010)
10.1016/j.bmc.2012.07.022
Discovery of structurally-diverse inhibitor scaffolds by high-throughput screening of a fragment library with dimethylarginine dimethylaminohydrolase.
Thomas W. Linsky (2012)
10.1002/cmdc.201300557
Developing an Irreversible Inhibitor of Human DDAH‐1, an Enzyme Upregulated in Melanoma
Yun Wang (2014)
10.1016/j.biopha.2018.12.117
Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro.
J. Hulin (2019)
10.1517/13543776.2013.788645
Biological activities of guanidine compounds, 2008 – 2012 update
F. Sa̧czewski (2013)
10.3390/molecules21050615
Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development
R. B. Murphy (2016)
10.3109/14756366.2011.573480
Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): A focus on selectivity over arginase
J. Kotthaus (2012)
Semantic Scholar Logo Some data provided by SemanticScholar